Get started
Author

Niels Fristrup

Observed names: Fristrup, Niels, N Fristrup, N. Fristrup
ORCID: 0009-0006-4442-0535
Observed ORCID: 0009-0006-4442-0535
OpenAlex ID: A5020909384
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
2016 · Jakob Hedegaard, Philippe Lamy, et al. · Cancer Cell · 639
PDF
Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitro
2009 · Lars Dyrskjøt, Marie S. Ostenfeld, et al. · Cancer Research · 363
Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties
2014 · Marie Stampe Ostenfeld, Dennis K. Jeppesen, et al. · Cancer Research · 294
PDF
Transcriptome-wide profiles of circular RNA and RNA-binding protein interactions reveal effects on circular RNA biogenesis and cancer pathway expression
2020 · Trine Line Hauge Okholm, Shashank Sathe, et al. · Genome Medicine · 201
PDF
Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer
2014 · Iver Nordentoft, Philippe Lamy, et al. · Cell Reports · 150
PDF
miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors
2009 · M S Ostenfeld, J B Bramsen, et al. · Oncogene · 143
The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer
2011 · S B Villadsen, J B Bramsen, et al. · British Journal of Cancer · 125
PDF
Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer
2012 · Jens R. Laurberg, Anne S. Brems‐Eskildsen, et al. · British Journal of Urology · 101
Cathepsin E, Maspin, Plk1, and Survivin Are Promising Prognostic Protein Markers for Progression in Non-Muscle Invasive Bladder Cancer
2012 · Niels Fristrup, Benedicte P. Ulhøi, et al. · American Journal Of Pathology · 82
PDF
Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscle–Invasive Bladder Cancer
2012 · Niels Fristrup, Karin Birkenkamp-Demtröder, et al. · American Journal Of Pathology · 77
PDF
High Expression of Karyopherin-α2 Defines Poor Prognosis in Non–Muscle-Invasive Bladder Cancer and in Patients with Invasive Bladder Cancer Undergoing Radical Cystectomy
2011 · Jørgen Bjerggaard Jensen, Pia Pinholt Munksgaard, et al. · European Urology · 75
Low ANXA10 expression is associated with disease aggressiveness in bladder cancer
2011 · P P Munksgaard, F Mansilla, et al. · British Journal of Cancer · 47
PDF
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial
2024 · Laura Iisager, Johanne Ahrenfeldt, et al. · BMC Cancer · 45
PDF
A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response
2012 · T Schepeler, P Lamy, et al. · Oncogene · 40
Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic
2023 · Iben Lyskjær, Laura Iisager, et al. · Clinical Cancer Research · 37
PDF
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression
2009 · Frederikke Lihme Egerod, Annette Bartels, et al. · BMC Cancer · 33
PDF
Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma
2024 · Jakob N. Henriksen, Charlotte U. Andersen, et al. · Clinical Genitourinary Cancer · 9
PDF
KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer – an observational trial. Study protocol
2024 · Laura Iisager, Johanne Ahrenfeldt, et al. · Acta Oncologica · 9
PDF
Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study
2019 · Niels Fristrup, Frede Donskov · Clinical Genitourinary Cancer · 7
PDF
Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab
2025 · Mette Syberg Jespersen, Jesper Andreas Evers Palshof, et al. · Clinical Genitourinary Cancer · 5
PDF
Trends in kidney cancer: exploring the impact of sex and age on stage of disease, and prognosis during the past three decades in Denmark—a DaRenCa study
2025 · Johanne Ahrenfeldt, Jesper Jespersen, et al. · European Journal of Epidemiology · 5
PDF
Recurrence patterns following nephrectomy for renal cell carcinoma in a Danish nationwide cohort
2024 · Goran Bencina, Rolf Billeskov, et al. · BJUI Compass · 5
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol
2025 · Jakob N. Henriksen, Charlotte U. Andersen, et al. · Acta Oncologica · 3
PDF
Lifestyle and Clinical Factors in a Nationwide Stage III and IV Renal Cell Carcinoma Study
2023 · Nessn Azawi, Freja Ejlebaek Ebbestad, et al. · Cancers · 3
PDF
Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC
2026 · Rikke Andersen, Mette Syberg Jespersen, et al. · European Journal of Cancer · 2
PDF
Works count: 100
Citation count: 2,511
H-index: 16
I10-index: 16
Year
Topic
Type